Drug intelligence / Profile preview

BE-102

Development stage: Preclinical
Lead developer: Be Biopharma
Modality: Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

BE-102 is a first-in-class B Cell Medicine (BCM) engineered using artificial intelligence-guided protein design to modify primary human B cells to produce alkaline phosphatase (ALP), an enzyme deficient in people living with hypophosphatasia (HPP). A single infusion of BE-102 has the potential to express sustained therapeutic levels of ALP, with flexibility for titration and/or re-dosing if needed, and does not require pre-conditioning. The therapy aims to transform the standard of care for HPP by providing continuous enzyme replacement through modified B cells[1][3].

Other names: ALP-BCM

Targets

ALPL (Tissue-nonspecific alkaline phosphatase)

Beyond the preview

Go deeper on BE-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BE-102.

Explore the full profile